Q Conference Call

Transcription

1 November 4, 2015 Q Conference Call 1

2 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing. These and other risks and uncertainties are detailed in the Company s Annual Report. 2

3 Today on the Call Simon Moroney CEO Jens Holstein CFO Claudia Gutjahr-Löser Head of Corporate Communications & IR 3

4 The MOR Portfolio Program Indication Target Discovery Preclinic Phase 1 Phase 2 Phase 3 Unpartnered MOR208 NHL CLL CD19 ALL MOR202 Multiple myeloma CD38 MOR107 Fibrosis AT2-R Immuno-oncology program (Immatics) Cancer Various 6 Programs Various Various Co-development & co-promotion MOR209/ES414 (Emergent) MOR106 (Galapagos) Immuno-oncology program (Merck Serono) Prostate cancer Inflammation Cancer PSMA / CD3 Undisclosed Undisclosed 4

5 MOR208 Multiple Studies Commencing in 2015 and 2016 NEXT STEPS Phase 2 trial with LEN in 2 nd line R/R DLBCL to start in Q Phase 2 trial with IDE in CLL in BTKi-failures to start in Q Phase 3 combo trial with BEN in 2 nd line R/R DLBCL aimed to start in 2017 Update on NHL monotherapy planned at ASH 2015 NHL DLBCL * Phase 2: MOR208 mono (N=92) Phase 2: MOR208 (12mg/kg) plus lenalidomide (N=80) Safety evaluation leading into anticipated pivotal study (12 mg/kg MOR208 plus bendamustine), N~320 CLL Phase 2: MOR208 (12mg/kg) plus idelalisib, BTKi-failures, N=120 Ph. 2 (ongoing OSU IIT): R/R & naive CLL & Richter s Transformation, MOR208 (9mg/kg) plus LEN, N=50 ALL Phase 2 (St. Jude s IIT): Pediatric ALL, MOR208 (12mg/kg) plus NK cells, N=13 Phase 3 Phase 2 IIT *no outlook given beyond

6 MOR202 Updated Clinical Data 15 th International Myeloma Workshop Data from patients in cohorts 5 who received > 1 treatment cycle *Updated data from 07 September 2015 Encouraging Activity and Long Lasting Tumor Control Already Demonstrated With Low Doses of MOR202 6

7 Progress in Partnered Programs MOR103/GSK Licensed to GSK. GSK is responsible for all development and commercialisation of MOR103 BAROQUE (RA Phase IIb) ongoing, initial clinical read-out 2016 Potential for disease modification & analgesic activity in hand osteoarthritis (HOA) Phase 2 in HOA to start in 2016 BAY Partnered program with Bayer HealthCare Start of phase 1 in hemophilia Antibody targets the tissue factor pathway inhibitor (TFPI), a major inhibitor of tissue factor-initiated blood clotting Milestone payment received (Q4) Gantenerumab Partnered program with Roche Update from Roche at Q3 call SCarlet RoAD and Marguerite RoAD will continue as open label studies Roche will explore higher doses of gantenerumab 7

8 New Partnerships Partnership focusing on G-protein coupled receptors (GPCRs) Innovative technology for production of GPCRs Challenging target class to make antibodies against Partnership provides access to new cancer targets Access to intracellular cancer targets, which are presented as peptides on cell surface In feasibility study, antibodies against HLA-peptide complexes were identified 8

9 The MorphoSys Pipeline 25 Clinical Programs, 104 Total Program Partner Target Disease Area Discovery Preclinic Phase 1 Phase 2 Phase 3 Bimagrumab (BYM338) Novartis ActRIIB sibm (musculoskeletal) Guselkumab (CNTO1959) Janssen IL23p19 Psoriasis Gantenerumab Roche Amyloid-ß Alzheimer s disease MOR208 - CD19 ALL, CLL, NHL MOR103/GSK GSK GM-CSF Inflammation MOR202 - CD38 Multiple myeloma BHQ880 Novartis DKK-1 Multiple myeloma CNTO3157 Janssen - Inflammation CNTO6785 Janssen - Inflammation LFG316 Novartis C5 Eye diseases LJM716 Novartis HER3 Cancer BPS804 Mereo/Novartis Sclerostin Brittle bone syndrome Tarextumab (OMP-59R5) OncoMed Notch 2 Solid tumors VAY736 Novartis BAFF-R Inflammation MOR209/ES414 Emergent PSMA/CD3 Prostate cancer Anetumab Ravtansine (BAY ) Bayer Mesothelin (ADC) Solid tumors BAY Bayer TFPI Hemophilia BI BI IGF-1 Solid tumors NOV 7 Novartis - Eye diseases NOV 8 Novartis - Inflammation NOV-9 Novartis - Diabetic eye diseases NOV-10 Novartis - Cancer NOV-11 Novartis - Blood disorders PF Pfizer 4-1BB Solid tumors Vantictumab (OMP-18R5) OncoMed Fzd 7 Solid tumors MOR106 Galapagos - Inflammation MOR107 (LP2) - AT2-R Fibrosis Immuno-oncology program Merck Serono - Cancer Immuno-oncology program Immatics - Cancer 6 MOR programs - - Various In addition, 26 partnered programs in pre-clinic, and 43 partnered programs in discovery Most advanced development stage 90 Partnered Programs 13 MOR Programs 1 Outlicensed Program 9

10 Income Statement in million* 9-Months Months 2014 Revenues % Operating Expenses Research and Development # % General and Administrative % Total Operating Expenses % Other Income Earnings before Interest and Taxes (EBIT) 34.7 (3.7) Finance Income Income Tax (Expenses)/Income (8.8) 0.3 Consolidated Net Profit/(Loss) 28.2 (2.0) Diluted Net Profit/(Loss) per Share 1.07 (0.08) # Split of R&D Expenses, in million 9-Months Months 2014 Proprietary R&D Expenses (incl. Technology Development) % Partnered Discovery Expenses % * Differences due to rounding 10

11 Segment Reporting in million* 9-Months Months 2014 Proprietary Development Segment Revenues Operating Expenses Segment EBIT 26.5 (12.7) Partnered Discovery Segment Revenues Operating Expenses Segment EBIT * Differences due to rounding 11

12 Balance Sheet in million* Sep 30, 2015 Dec 31, 2014 Assets Cash, Cash Equivalents Available-for-sale Financial Assets Bonds, Available-for-sale Financial Assets Classified as Loans and Receivables Other Current Assets Total Non-current Assets Total Assets Liabilities & Stockholders Equity Total Current Liabilities Total Non-current Liabilities Total Stockholders Equity Total Liabilities & Stockholders Equity As of 30/09/2015, MorphoSys held liquid funds and marketable securities as well as other short-term and long-term financial assets in the amount of million (31/12/2014: million) * Differences due to rounding 12

13 Financial Guidance 2015 in million Guidance 2015 Group Revenues 101 to 106 Proprietary R&D Expenses (incl. Technology Development) 56 to 63 EBIT 9 to 16 13

14 Q Conference Call Q&A Session

15 Thank You Corporate Communications & Investor Relations Phone +49 (0)89 / Fax +49 (0)89 / investors@morphosys.com HuCAL, HuCAL GOLD, HuCAL PLATINUM, CysDisplay, RapMAT, aryla, Ylanthia and 100 billion high potentials are registered trademarks of MorphoSys AG. Slonomics is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.